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REVIEW
SMALL VOLUME HYPERTONIC RESUSCITATION OF
CIRCULATORY SHOCK
Mauricio Rocha-e-Silva and Luiz F. Poli de Figueiredo
ROCHA-E-SILVA et al. Small volume hypertonic resuscitation of circulatory shock. CLINICS 60(2):159-172, 2005.
Small volume hypertonic resuscitation is a relatively new conceptual approach to shock therapy. It was originally
based on the idea that a relatively large blood volume expansion could be obtained by administering a relatively small
volume of fluid, taking advantage of osmosis. It was soon realized that the physiological vasodilator property of hypertonicity
was a useful byproduct of small volume resuscitation in that it induced reperfusion of previously ischemic territories, even
though such an effect encroached upon the malefic effects of the ischemia-reperfusion process. Subsequent research disclosed
a number of previously unsuspected properties of hypertonic resuscitation, amongst them the correction of endothelial and
red cell edema with significant consequences in terms of capillary blood flow. A whole set of actions of hypertonicity upon
the immune system are being gradually uncovered, but the full implication of these observations with regard to the clinical
scenario are still under study. Small volume resuscitation for shock is in current clinical use in some parts of the world, in
spite of objections raised concerning its safety under conditions of uncontrolled bleeding. These objections stem mainly
from experimental studies, but there are few signs that they may be of real clinical significance. This review attempts to
cover the earlier and the more recent developments in this field.
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Hypertonic salt solutions (HS) have been viewed with
interest as possible therapeutic agents for hemorrhage since
1917, when Penfield published a report showing that a rela-
tively small volume of 1.8% NaCl induced a transient re-
covery of the hypotension caused by blood loss in dogs1.
Later, a 5% NaCl solution was unsuccessfully tried for the
treatment of Buerger´s disease2. No other interesting data on
this interaction appeared in press till the sixties, when Baue
et al. and Messmer et al. reported equally transient effects
of 5% NaCl and 7.5% NaHCO3 in severely hemorrhaged
dogs3-5. Gazitua et al. demonstrated that hyperosmotic NaCl
solutions induced vasodilation when selectively infused in
the renal, coronary, and limb circulations6.
However, interest for the use of hypertonic solutions for
the treatment of shock was enhanced when we showed that
severely hemorrhaged dogs (40 ml/kg blood loss) re-
sponded with a restored arterial pressure and cardiac out-
put following IV bolus injections of 4 mL/kg of 7.5% NaCl,
a volume equivalent to only 10% of the volume of shed
blood7. Long term survival was observed in all 10 HS
treated dogs; in contrast, control animals, treated with an
equal volume of isotonic saline, responded with neither
hemodynamic improvement, nor survival.
In the same year, Fellippe et al. pioneered human stud-
ies: Hypertonic NaCl solutions (7.5% in successive 50 ml
aliquots) given to patients in refractory shock at an emer-
gency intensive care unit induced hemodynamic benefits.8
These reports stimulated hundreds of studies, including ex-
perimental and more than 60 clinical trials with 7.5% NaCl
in the treatment of several conditions, such as hemorrhagic,
cardiogenic, and septic shock, as well as a volume support-
ing solution during major surgical procedures.9 Several
groups confirmed our findings that a small volume of 7.5%
NaCl, infused to animals which had lost 40 – 50% of their
blood volumes, rapidly restored arterial pressure, cardiac
output and blood flows to vital organs.10-14 The hypertonic
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saline dextran (HSD) association, combining the
hyperosmotic effects of NaCl to the hyperoncotic effects
of dextran12 added new conceptual and practical possibili-
ties. In this review we cover a number of significant aspects
of the interaction of hypertonic solutions with severe
hemorrhage and circulatory shock.
PHYSICAL PROPERTIES OF HS AND HSD
A simple physical interaction is mainly responsible for
the initial effect of HS, namely a significant plasma vol-
ume expansion. The standard dose of HS (4 mL/kg of 7.5%
NaCl) adds a load of 5.12 mEq Na+/kg body weight. In
theory, if diluted exclusively into the plasma volume of a
normovolemic animal (40 mL/kg), this Na+ load should in-
crease plasma Na+ to approximately 263 – 268 mEq/L (128
mEq/l above the basal level of 135-140 mEq/L). However,
such values are never observed in laboratory or clinical tri-
als. Figure 1 shows the only way by which such a concen-
tration may be achieved: the full Na+ load (5.12 mEq/kg)
must be administered intravenously over 10 seconds, and
plasma Na+ read immediately thereafter. Under these con-
ditions plasma Na+ effectively rose to 267 mEq/l. Such a
rapid injection is only feasible if we employ a saturated
30% NaCl solution, thereby reducing the injected volume
to 1 mL/kg. Figure 1 also shows that using the standard
7.5% NaCl HS, the same Na+ load can be injected within
one minute: in this manner, it increases plasma Na+ con-
centration by 25 mEq/L, from 140 to 165 mEq/L. The lat-
ter value is almost identical to that observed one minute
after the ten second 30% NaCl injection. The 25 mEq/L
Na+ increase is the correct theoretical value for the dilu-
tion of 5.12 mEq/kg across the entire extracellular space
(approximately 200 ml/kg). Finally, Figure 1 shows that
when the Na+ load is given over 2 min, the observed Na+
peak is 152 mEq/L. Again this value is almost identical to
that obtained at 2 min following the ten seconds injection.
More significantly, this is also the Na+ peak value typically
observed in experimental and clinical trials with HS15. It
clearly demonstrates that the extravascular compartment
has been expanded by HS, a fact which can only be ac-
counted for by assuming that water has been osmotically
drawn out of the intracellular compartment by HS. In sum-
mary, these three decay curves of Na+ indicate that the theo-
retical distribution space is the intravascular compartment
at zero time, the extracellular space at 1 min. At 2 min, the
Na+ decay from 165 to 152 mEq/L indicates that the extra-
cellular compartment has been expanded by approximately
8% to 216 ml/kg. These theoretical considerations apply
to a normovolemic animal. In an oligovolemic animal, af-
ter severe bleeding, extracellular expansion would be theo-
retically greater. In our original paper,7 using plasma vol-
ume and hematocrit measurements after hypertonic resus-
citation, we detected an initial increment in plasma volume
of 11 mL/kg. This represents a 30% increase of pre-exist-
ing volumes, or about 2.75 mL of plasma for each mL of
the injected solution. In contrast, standard isotonic solu-
tions only induce an expansion of 0.33 mL for each mL
injected, as a consequence of its distribution throughout
the extra vascular compartment.
The association of 6% dextran-70 to the 7.5% NaCl so-
lution (HSD) introduced by Kramer et al.,12 somewhat en-
hances the initial plasma expansion. However, it’s most im-
portant effect is the maintenance of intravascular expansion
for longer periods, thus prolonging the hemodynamic and
metabolic benefits of the hypertonic solutions.11,12,16 Figure
2 shows plasma expansion produced by isotonic crystal-
loid, HS and HSD. The addition of HSD alters the dynam-
ics of fluid shift by generating an extra oncotic gradient
across the endothelial barrier. This further expands the in-
travascular compartment, but now at the expense of fluid
moved from the interstitial space. The 6% Dextran-70 so-
lution exerts an oncotic pressure of 70 mm Hg, greater than
that observed with a similar concentration of human albu-
min. Results described for HSD have also been demonstrated
with HSS, in which 6% hetastarch is added to the 7.5% NaCl
solution.17 Figure 3 summarizes the physical properties of
HS and HSD. The respective reflection coefficients of the
endothelial barrier and cellular membrane to Na+ must be
considered in the determination of the osmotic force gen-
erated by the gradients established after the use of hyper-
tonic saline solution. The endothelial barrier reflection co-
Figure 1 - Sodium plasma levels after intravenous injections of 5.12
mEq/kg de Na+ to normovolemic anesthetized dogs. This sodium load
was infused in three different regiments: as 30% NaCl in 10 seconds
(in circles), as 7.5% NaCl in one minute (in triangles), and as 7.5%
NaCl in two minutes (in squares).
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efficient is 0.1, while the cell membrane coefficient is 1.
Thus, for instance, a gradient of 25 mOsm/L exerts an os-
motic pressure of 500 mmHg across the cellular membrane,
but only 50 mmHg across the endothelial membrane. Equi-
librium will be reached 1 min across the endothelial mem-
brane, in 2 min across the cell membrane. Thus, the intra-
vascular expansion induced by hypertonic resuscitation
occurs from the intracellular compartment and not from the
interstitial compartment, which is also expanded. This fluid
shift from the intracellular to the extracellular compart-
ment may be regarded as beneficial, since during shock
states, ischemia-reperfusion, extracorporeal circulation
and sepsis, among other conditions, there is cellular
edema, due to the action of inflammatory mediators and
because of sodium/potassium pump dysfunction in the cel-
lular membranes.18 Figure 3 also shows how dextran en-
hances the water shift from the interstitial to the intravas-
cular compartment.
PHYSIOLOGICAL PROPERTIES OF HS/HSD
When a 4 ml/kg of 2,400 mOsm/L sodium salt solution
is administered to animal previously submitted to severe
blood loss, a cardiovascular improvement consisting of par-
tial recovery of mean arterial pressure and cardiac output
is observed. It has been variously attributed to plasma vol-
ume expansion, vasodilatation in several vascular beds6
and to a direct cardiac inotropic effect.19,20 Renal and me-
senteric vasodilation6,7 appear to be particularly important
because hemorrhage induces critical flow restrictions to
these territories.
Acid base equilibrium is also affected by HS. An initial
enhancement of the metabolic acidosis induced by shock
is generally observed and has been attributed to
hyperchloremic acidosis. This is, however, followed by a
recovery towards baseline levels, which has been attributed
to a recovery of nutrient flow through previously constricted
territories.1,20,21,22
Catecholamine and vasopressin release are also affected
by the hemorrhage – HS/HSD interaction. Hemorrhage in-
duces elevated levels of vasopressin and catecholamines;
these effects are partially offset by resuscitation with HS/
HSD.23 Some of these physiological responses to hyperto-
nicity will be re-examined in the following paragraphs.
Effects of HS on the microcirculation. The classical
papers of Mazzoni et al.24,25 demonstrated that the main
sources for the observed plasma volume expansion after
7.5% NaCl injection are the red blood cells and the en-
dothelium, mainly on account of their immediate physi-
cal contact with the intravascular hypertonicity. These
cell species, which had been made edematous by shock,
lose 8% of their volumes directly to the intravascular com-
partment. Apart from the volume expansion, this fluid shift
has important hemodynamic consequences, at the micro-
circulatory level. The hemorrhage induced edema of the
endothelial and of the red blood cells are of critical im-
portance in terms of capillary flow, where the ratio between
the vascular lumen and red blood cell cross section ap-
proaches unity. Endothelial edema reduces the lumen and
red cell edema increases red cell cross section, thereby in-
creasing viscosity and hydraulic resistance. Under these
circumstances, cellular edema compromises the microcir-
culatory blood flow. Small volume hypertonic resuscita-
tion instantly corrects this geometric anomaly, whereas
larger volume isotonic resuscitation will only correct this
over a much more extended period, after the successful
correction of oxygen supply.24,25
Figure 2 - Plasma volume expansion in ml expansion per ml infused
after 32 ml/kg isotonic NaCl, 4 ml/kg 7.5% NaCl, or 4ml/kg 7.5%
NaCl-6%Dextran-70.
Figure 3 - Summary of physical properties of intravenously injected
HS/HSD. Hypertonic Na+ moves water osmotically across the cell
membrane; hyperoncotic dextran or hetastarch moves water oncotically
across the endothelial barrier.
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These microcirculatory disturbances have been impli-
cated in the origin of sepsis and multiple organ dysfunc-
tion that occur after an initially successful resuscitation of
posttraumatic shock.26 The resulting sustained splanchnic
vasoconstriction may cause gut mucosal ischemia and con-
sequent compromise of its integrity, with the consequent
predisposition to bacterial and toxin penetration from the
intestinal lumen into the systemic circulation. Microcircu-
lation in the gut mucosa may be even more severely com-
promised during the reperfusion period. This secondary ef-
fect, mediated by oxygen free radicals, also results in cap-
illary lumen narrowing, leukocyte adhesion and activation,
and stimulation of several inflammatory mediators and
cytokines, which may cause local tissue and remote organ
injuries.26-28
Under these conditions, hypertonic solutions may pro-
duce several beneficial effects through the rapid
hemodynamic restoration at the macro and microcirculatory
levels. Based on these observed effects in posttraumatic
shock, studies with 7.5% NaCl solutions, with and without
dextran or hetastarch, have been performed using several
models of sepsis and septic shock. Benefits have
been observed at the level of global and regional
hemodynamics.29-31
Effects of HS on the vascular resistance. The hyperto-
nicity induced by the 7.5% NaCl injection is responsible
for the increased blood flow in the peripheral circulation
and in the microcirculation as a consequence of a reduced
vascular resistance, primarily by arteriolar vasodilatation.
This response is caused by a direct relaxant effect of hyper-
tonicity on vascular smooth muscle.
The reduction in blood viscosity, by the hemodilution
rapidly induced by the hypertonic solution, also contrib-
utes to the reduction in vascular resistance. The use of 7.5%
NaCl in shock produces vasodilatation and increased re-
gional blood flow to coronary32, renal6,33, intestinal14,19,34 and
skeletal muscle14 circulations.
Effects of HS on myocardial contractility. The
hemodynamic benefits observed after 7.5% NaCl have been
partially attributed to a direct cardiac inotropic effect in-
duced by hypertonicity.35,36 However, an evaluation of left
ventricular contractility after 7.2% NaCl / 6% hetastarch
in anesthetized, stable patients without cardiovascular dis-
ease, did not demonstrate any clinically relevant positive
inotropic effect. All hemodynamic benefits were therefore
attributed to the combination of volume expansion and de-
creased afterload.37
Some authors showed no direct inotropic effect with
hypertonic solutions in the treatment of hemorrhagic
shock,38 while others showed negative inotropic effects in
normovolemic dogs.39 Thus, whether or not hypertonic so-
lutions have a direct positive inotropic effect contributing
to the hemodynamic benefits remains controversial.
Additional regional effects. Improvements in renal func-
tion have been observed after HSD infusion to animals in
shock. This benefit is probably multifactorial, resulting from
volume expansion, general hemodynamic improvement and
increased renal blood flow.40
A great benefit with hypertonic resuscitation has been
observed on cerebral hemodynamics during hemorrhagic
shock, particularly in the presence of intracranial hyperten-
sion and systemic hypotension.41,42 The rapid restoration of
the arterial pressure associated with a reduction in intracra-
nial hypertension induced by hypertonic solutions suggests
a potential clinical application of these solutions for trauma
victims with head injury and associated lesions with hypo-
tension, a subset of trauma victims with poor prognosis.43
In the clinical trials, patients with low Glasgow coma
score and hypotension after trauma benefited from an ini-
tial infusion of hypertonic solutions.44
IMMUNE AND INFLAMMATORY EFFECTS OF HS/
HSD
The physical and physiological effects of small volume
hypertonic resuscitation are essentially short term in dura-
tion, which contrasts with the long term survival produced
by HS. The long-term effects of hypertonic resuscitation
which shall now be discussed only began to be adequately
evaluated in the last decade.
The role of the dextran component as a oxygen free radi-
cals scavenger and the role of HSD as an inhibitor of
leukocyte activation had already been recognized.45 More
recently, a series of experiments have shown that hypertonic
saline solution, even without dextran, significantly interferes
with the immune responses, both in vitro and in vivo.46-57
The addition of hypertonic saline solution to a
lymphocyte culture media, in concentrations similar to
those obtained with systemic infusion of 4 mL/kg of 7.5%
NaCl in humans, determined a significant increase in
lymphocyte proliferation.46 The addition of prostaglandin
E2 (PGE2) to the culture media, in the absence of hypertonic
saline, caused a reduction in T-cells proliferation, when
compared to control cultures. On the other hand, when
hypertonic saline was added to the culture media contain-
ing PGE2, there was a complete reversal on the PGE2-in-
duced immunosupression.47,48
These in vitro findings were confirmed in vivo using a
hemorrhagic shock model in mice, in which the infusion
of 7.5% NaCl reversed the cellular immune function depres-
sion that occurs after hemorrhage. Plasma levels of several
cytokines were determined, and it was concluded that hyper-
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tonic saline solution prevents immunossupression probably
by decreasing plasma levels of IL-4 and PGE2.48 A double
hit model in mice, hemorrhagic shock, followed by resus-
citation then by cecal puncture 24 hours later, showed that
7.5% NaCl resuscitation was associated to a significant de-
crease in mortality 72 hours after peritonitis induction, com-
pared to conventional isotonic resuscitation. Moreover, a
significant reduction in pulmonary and hepatic changes af-
ter hypertonic solutions was observed.49 Neutrophile acti-
vation after the trauma-hemorrhagic shock interaction is
significantly limited by treatment with HS.50 Significant re-
ductions have been detected in bacterial translocation and
pulmonary lesions in rats with hemorrhagic shock which
were treated with hypertonic saline solution.51 More recently
it has been shown that polymorph nuclear rolling and stick-
ing, as well as lung expression of ICAM 1, and leakage are
inhibited by treating severe hemorrhage with HS. 52,53 It has
also be shown that hypertonic saline inhibits neutrophile
priming via attenuation of p38 MAPK signaling.54 Inhibi-
tion of alveolar macrophage activation by prevention of the
systemic oxidative stress due to gut ischemia/reperfusion
has also been claimed.55
A possible interaction between hypertonic saline for the
treatment of hemorrhage, apoptosis, and tissue damage of
the small intestine has also been recently suggested.57 In
another study, we have shown that hypertonic saline may
exert its long-term benefits after hemorrhagic shock by
modulating bone marrow apoptosis.58, a mechanism that has
been linked to sepsis and multiple organ dysfunctions.59
Hypertonic saline resuscitation may also influence the
transcriptional, functional and protein expression of genes
related to Matrix metalloproteinases (MMPs) and their spe-
cific physiological inhibitors, tissue inhibitors of
metalloproteinases (TIMPs), which are thought to play an es-
sential role in tissue repair, cell death and morphogenesis.60
Based on these evidences, it has been suggested that
resuscitation with hypertonic saline solutions present sig-
nificant potential as an immunomodulator agent for trauma
victims.61 Hypertonic saline induced systemic, regional and
immunomodullatory beneficial effects were recommended
for the potential use as treatment of septic shock.62,63. How-
ever, all this evidence requires additional research and care-
ful evaluation in clinical trials using these solutions. A re-
cent review by Kolsen-Petersen suggests that many of the
effects described in animal models may be inapplicable to
the clinical scenario.64
ASSOCIATION WITH OXYGEN CARRIERS
There is a great interest in the association of hypertonic
saline, which causes hemodilution with oxygen carriers,
particularly modified cell-free hemoglobins, which are cur-
rently undergoing phase III clinical trials. It has been well
demonstrated that small volumes of these solutions restore
arterial pressure in animals in hemorrhagic shock. However,
this benefit is achieved through marked vasoconstriction
secondary to nitric oxide scavenging by the free
hemoglobin.
Severe pulmonary hypertension and coronary, splanch-
nic and renal vasoconstriction have been also attributed to
cell-free hemoglobin solutions.65-68 The association of
hypertonic sodium acetate solution, 2400 mOsm/L, with
cell-free hemoglobin limited the potent arteriolar vasodi-
lator properties of this variety of hypertonic solution, be-
cause of the marked hemoglobin-induced vasoconstriction.
With this combination, it has been shown that the associa-
tion of peripheral vasodilatation, induced by the hypertonic
solution, with the pulmonary hypertension, induced by the
hemoglobin, may result in severe hemodynamic stability.67
Slower infusions of the combined hypertonic-hemoglobin
solution, the use of inhaled nitric oxide to selectively re-
verse pulmonary hypertension, 68 and the use of encapsu-
lated hemoglobin,69 which is definitely less vasoconstric-
tive, are some of the potential alternatives that have been
tested to expand the benefits of hypertonic saline resusci-
tation for the next years.
CLINICAL EXPERIENCE AND PERSPECTIVES
A substantial clinical experience has accumulated re-
garding the use of 7.5% NaCl solutions.17 Such studies have
provided valuable insights regarding safety and efficacy of
hypertonic saline solutions. A majority of patients received
these solutions as the initial treatment for posttraumatic hy-
potension followed by standard-of-care isotonic crystalloid
solutions, both in pre-hospital or in the emergency room
environment, including several prospective and double-
blind studies.70-78
These patients have been submitted to extensive clini-
cal and laboratory evaluation, demonstrating the highly
desirable safety profile of the tested solutions even when
infused to very sick patients such as trauma victims with
immediate risk of death from hypovolemia, hemodynamic
instability and severe associated lesions. Studies performed
in patients undergoing cardiovascular surgeries and in those
who are critically ill in intensive care units provide data
regarding the effects of hypertonic saline solutions in sub-
jects with associated pre-existing diseases and with limited
organ reserve, situations which are seldom seen in young
trauma victims.
Questions raised from clinical trials have been addressed
by experimental studies using clinically relevant large ani-
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mal models, particularly addressing concerns and perspec-
tives with the use of hypertonic solutions for uncontrolled
hemorrhage and head trauma.
EFFICACY
The ultimate test of efficacy for treatment of trauma with
shock is enhanced survival, followed by other important
endpoints such as reduced occurrence of multiple organ
dysfunctions and of long-term disabilities. A number of re-
ports have demonstrated significantly increased efficacy in
patients treated with hypertonic saline followed by stand-
ard-of-care crystalloid infusion, when compared to equiva-
lent patients receiving standard-of-care.
In the first performed trial, by Younes et al, 105 patients
in hypovolemic shock patients treated in our institution
with hypertonic saline showed a significant initial improve-
ment of arterial pressure and reduced intravenous fluid re-
quirements. No significant difference in mortality was de-
tected. 70 In a subsequent study in which 212 hypotensive
patients were enrolled, the same group showed that hyper-
tonic saline as initial treatment caused a significant de-
crease in long-term mortality rate for the subpopulation
with an entry mean arterial pressure below 70 mm Hg. 752
The largest controlled trial so far performed, the USA
multicenter trial enrolled 422 patients.75 A significant in-
crease in survival for the HSD treated patients in the
subpopulation requiring surgery was shown. It also showed
a greater incidence of adult respiratory distress syndrome,
renal failure and coagulopathy in the standard-of-care alone
treatment group. An extensive evaluation of coagulation
profile and detailed laboratory workout demonstrated safety
of HSD in this severely injured population. 75
Hypotensive patients sustaining head injury with Glas-
gow Coma Scale scores of 8 or less which received hyper-
tonic saline treatment presented higher survival to hospi-
tal discharge. This was demonstrated in a multicenter trial
77
 as well as in a meta-analysis of individual patients from
all the known clinical trials.44 A meta-analysis conducted
on the individual patient records from controlled clinical
studies on trauma demonstrated a significant increase in sur-
vival favoring HSD versus standard of care.78
SAFETY AND CONTROVERSIES
Bleeding. Since hypertonic saline resuscitation induces
an immediate restoration of both cardiac output and arte-
rial pressure, vasodilatation and hemodilution, several in-
vestigators raised concerns that these effects could over-
come homeostatic mechanisms, such as vasoconstriction
and local tamponade, and even hypotension. The solutions
would therefore represent a potential risk for increased in-
ternal bleeding in humans, 79,80 as shown in a series of ex-
perimental models of uncontrolled hemorrhage in rats,81-85
and pigs.86
These concerns were highlighted by the very controver-
sial study which challenged the guidelines recommended
by the Advanced Trauma Life Support Course,87 for the re-
suscitation of penetrating trauma victims and hypotension
with large volumes of isotonic crystalloid solutions.88 This
study suggested that standard-of-care pre-hospital and emer-
gency room fluid infusion for these patients resulted in
higher mortality and morbidity than what was observed for
patients in whom delayed fluid resuscitation, i.e. after op-
erative bleeding control.88 Unfortunately, the study is marred
by a number of unresolved flaws.
On the other hand, the USA Multicenter Trial which
compared standard-of-care fluid infusion to HSD followed
by standard-of-care in the pre-hospital treatment of
posttraumatic hypotension demonstrated that penetrating
trauma victims with hypotension that received HSD pre-
sented higher arterial blood pressure and trends toward
higher survival and less complications, when compared to
standard-of-care fluid treatment alone.74 Similar results were
observed by a meta-analysis of posttraumatic hypotension
treated by hypertonic saline as the first fluid infused fol-
lowed by standard of care treatment.78 Based on these data,
we could speculate that the negative effects of large vol-
ume infusion of crystalloid solutions are not related solely
to increased arterial pressure but to factors related to the
isotonic solution itself. A trial comparing standard-of-care,
HSD and delayed resuscitation would be needed to estab-
lish the best means to treat posttraumatic hypotension. Such
a trial, conducted on sick human patients would however
be open to severe ethical criticism.
While such a trial remains problematic, we have per-
formed two studies comparing intra-abdominal blood loss
measured 20 minutes after the beginning of small volume
hypertonic saline bolus (4 mL/Kg 7.5% NaCl in 5 min),
large volume lactated Ringer’s (32 mL/kg in 15 min) or de-
layed resuscitation (no fluids). When administered, treat-
ment was infused after 20 minutes of uncontrolled
hemorrhage simulating a penetrating (Figure 4, iliac artery
tear)89 or a blunt abdominal injury (Figure 5, splenic rup-
ture)90. In both experimental models, untreated controls re-
mained in severe hypotension and low blood flows. Blood
loss was not significantly increased by either treatment, sug-
gesting that the hemodynamic benefits observed with fluid
treatment were not associated with increased bleeding,
which was directly measured after 40 minutes of uncon-
trolled bleeding. Our experimental data support observa-
tions of no increase in blood loss or blood product require-
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ment after HS or HSD in every human trauma trial of
posttraumatic hypotension. In most experimental studies
showing increased blood loss and mortality, fluid infusion
was started immediately after the induction of uncontrolled
hemorrhage, a scenario which is extremely uncommon fol-
lowing civilian and military trauma.81-84,86
Moreover, patients receiving hypertonic solutions in
these posttraumatic hypotension studies underwent extensive
laboratorial investigation, which showed that the coagula-
tion profile was not altered by the amount of dextran 70 in
the HSD formulation. Additionally, none of the studies with
trauma victims or those trials to test the intraoperative use
of HSD demonstrated any association between hypertonic
solutions and blood loss or with increased requirements of
blood products. In all studies so far performed, blood prod-
uct requirements have always been associated with the se-
verity and mechanism of injury, and not to the solution used.
In fact, a reduction in subsequent fluid requirements is a com-
mon finding after the use of HSD.78
The use of HSD during complex cardiovascular surger-
ies, in which hemostasis alterations are common,91 was not
associated with increased blood loss or increased blood
product requirements. On the other hand, the use hypertonic
solutions in cardiac and aortic surgeries has been frequently
associated with hemodynamic stability and less, rather than
more postoperative fluid requirements.92-95
Figure 4 - Mean arterial pressure, cardiac index and blood volume
loss during 40 minutes of uncontrolled intra-abdominal hemorrhage
from an iliac artery tear for the CT group (no fluids), HSD group (4
mL/kg over 5 min), and the LR group (32 mL/kg over 15 min).
Adapted from Bruscagin et al, 2002.89
Figure 5 - Mean arterial pressure, cardiac index and blood volume
loss during 40 minutes of uncontrolled intra-abdominal hemorrhage
from a splenic rupture for the CT20 group (no fluids, 20 min), CT40
(no fluids, 40 min); HSD group (4 mL/kg over 5 min), and the LR
group (32 mL/kg over 15 min). Adapted from Varicoda et al, 2003.90
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Overall, the common observation of less fluid require-
ments, no increase in blood products requirements, and
trends toward less morbidity and mortality with the use of
hypertonic solutions suggest that there is no increase in
bleeding associated with its use, even in patients sustain-
ing penetrating trauma or during complex cardiovascular
surgeries.
Hypernatremia and neurological dysfunction. A fre-
quent concern with hypertonic resuscitation is that it might
possibly induce significant hypernatremia with potentially
deleterious consequences. Such hypernatremia would of
course result from cellular dehydration produced by the os-
motic mechanisms already described. In severe
hypernatremia, evidence of cellular dehydration is mani-
fest much earlier in the central nervous system than in other
organs or systems. Symptoms of hypernatremia include leth-
argy, tremors, weakness, irritability, delirium, mental con-
fusion, seizures, coma and death. They occur in severe cases
and, particularly, in small children and in the elderly.
The use of hypertonic sodium solutions to rapidly cor-
rect hyponatremia in patients with severe malnutrition or
alcoholism may result in central pontine myelinolysis,
which is manifest through dysartria, paraparesis or paraple-
gia.96 Another described complication with hypertonic so-
dium solutions for the correction of hyponatremia in
neonates is the rupture of cerebral veins and intracranial
hemorrhage, caused by the retraction of the cerebral tissue.97
With these questions in the forefront of all clinical tri-
als, patients receiving 7.5% NaCl were carefully evaluated
for signs and symptoms of hypernatremia, particularly for
the associated neurological alterations. This was especially
true for patients at highest risk for neurological dysfunc-
tion and intracranial hypertension, i.e. those sustaining head
trauma and systemic hypotension.
Despite the fact that moderate hypernatremia and
hyperosmolarity have been detected in the overwhelming ma-
jority of patients receiving 7.5% NaCl solutions, there was not
a single case, among more than 1700 patients, of seizures, in-
tracranial bleeding or neurological deterioration induced by
the hypertonic solution.44,78 Necropsies and careful anatomic-
pathological studies of the brain tissues were performed in
trauma victims, and produced no evidence of central pontine
desmyelinization or of focal intracranial bleeding which could
be attributed to the use of 7.5% NaCl. 44,78
The short duration of the moderate hypernatremia, the
absence of pre-existing hyponatremia, the exclusion of chil-
dren and patients with chronic disabling diseases may have
contributed to the lack of hypernatremia-related undesir-
able effects. On the other hand, hypotensive patients with
head trauma and low Glasgow Coma Scale were one of the
subgroups that most benefited from 7.5% NaCl solutions
as the initial treatment, presenting better neurological out-
come and a significant increase in survival.44 Thus, 7.5%
NaCl-induced hypernatremia and hyperosmolarity were ac-
tually associated with neurological benefits, not with neu-
rological dysfunction.
The well demonstrated findings that hypertonic saline
induces favorable effects on both systemic hemodynamics
and intracranial pressure in laboratory and clinical settings
have stimulated a number of studies. In Figure 6, we show
that in hemorrhaged dogs sustaining a unilateral cryogenic
cerebral lesion, a small volume hypertonic saline bolus (4
mL/Kg 7.5% NaCl in 5 min) reduced intracranial pressure.
Mean arterial pressure was greater after large volume lac-
tated Ringer’s (32 mL/kg in 15 min), but increased intrac-
ranial pressure was also observed Both treated groups
showed similar improvement in cerebral perfusion pressure.
No fluid infusion was associated with worse cerebral and
systemic hemodynamics and greater increase in intraneu-
ral calcium at the penumbra area.98
Existing preliminary evidence supports the need for
controlled clinical trials evaluating hypertonic saline use
as resuscitative fluid in brain-injured patients with
hemorrhagic shock, as therapy for intracranial hypertension
resistant to standard therapy, as first line therapy for intrac-
ranial hypertension in certain intracranial pathologies, as
small volume fluid resuscitation during spinal shock, and
as maintenance intravenous fluid in neurocritical care
units.99,100 Bolus infusions of 7.5% NaCl or even of
23%NaCl were the only means to achieve sustained con-
trol of intracranial hypertension after every other known
measure failed.101
Although we cannot exclude that higher doses of hyper-
tonic saline might induce hypernatremia-related side effects,
it is also true that the prescribed dose cannot result in such
effects. However, it does seem prudent to avoid these solu-
tions for patients with the highest risk for severe neurologi-
cal disturbances induced by hypernatremia, i.e. patients
with chronic debilitating diseases and children.
Cardiac dysfunction. Experiments with anesthetized
animals in shock have shown that a rapid injection of 7.5
NaCl may cause hypotension and arrhythmia, caused by
hypertonicity-induced vasodilatation and reduction in pe-
ripheral vascular resistance.102 These events may be particu-
larly dangerous when the arterial pressure is very low be-
fore the infusion of the solution. This hemodynamic insta-
bility is directly dependent on the speed with which the
solution is being infused and may be avoided with infu-
sion times greater than two minutes.
The majority of trials with intraoperative use of 7.5%
NaCl has demonstrated physiologic benefits and no side-
effects.92-95 There is however one study in patients with myo-
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cardial dysfunction undergoing coronary artery bypass in
which pre-operative volume expansion with 250 mL of HSS
caused hypotension and transient left ventricular failure.103
This study showed that 7.5% NaCl solutions can be del-
eterious if rapidly infused in patients with ventricular dys-
function.104 In a similar study, in patients with cardiac dys-
function, in which the volume of 7.5% NaCl solution was
titrated to a target cardiac filling pressure, it was found that
a lower dosage was enough to achieve the desired
hemodynamic profile, with no hemodynamic instability.104
In a separate study, a fixed dose of HSD (250 mL) was
used during extracorporeal circulation in Jehovah’s witness,
with no hemodynamic changes and reduced fluid require-
ments in the postoperative period.95 A similar dose was used
in surgical procedures for correction of thoracic and ab-
dominal aortic aneurysms.92,93,105 These procedures are nor-
mally associated with sudden hemodynamic changes,
marked fluid loss to the third space and high incidence of
postoperative complications.106 The use of hypertonic sa-
line solutions resulted in hemodynamic stability and fluid
sparing in the postoperative period in these procedures.
The use of 7.5% NaCl solution to patients with
cardiogenic shock after right ventricular infarction also pro-
duced sustained hemodynamic benefits.107
When the whole population of 1700 patients in which
7.5% NaCl solutions were used is examined, there were no
cases of cardiac death. However, it seems prudent to recom-
mend caution with the use of hypertonic solutions in patients
with heart diseases. Rigorous monitoring is mandatory and
gradual and slower infusions should be employed. The safety
profile for the use of 7.5% NaCl solutions in children was
recently established by Rocha e Silva et al. during the sur-
gical correction of congenital cardiac defects.108
Hyperchloremic acidosis. Hypertonic NaCl (7.5%) so-
lutions induce a significant increase in chloride plasma lev-
els, and this could predispose to hyperchloremic acidosis.
Clinically relevant acidosis was observed in trauma victims
that were moribund on arrival and the acidosis was associ-
ated with pre-existing conditions such as cardiac arrest or
severe hypothermia.72 Despite hemodynamic and metabolic
improvement after 7.5% NaCl solutions in the majority of
patients, it is reasonable to suggest, based on the clinical
evidence, that these solutions should be avoided in patients
with preexisting severe acidosis, especially when such aci-
dosis follows cardiac arrest or prolonged pre-hospital times.
CONCLUSION
Based on the available clinical experience with 7.5%
NaCl solutions, we conclude that the use of hypertonic
solutions is safe, but it is prudent to avoid their use for a
Figure 6 - Mean arterial, intracranial and cerebral perfusion pressures
in hemorrhaged dogs sustaining an unilateral cerebral cryogenic lesion
for the CT group (no fluids), HSD group (4 mL/kg over 5 min), and
the LR group (32 mL/kg over 15 min). Intraneural calcium measured
from cerebral byopsies from the penumbra area and contralateral
hemisphere. Adapted from Balbino, 2001.98
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well defined patient population, i.e. moribund, or chronic
debilitating diseases. Although safety in children under-
going elective cardiac surgery has been demonstrated, ad-
ditional studies under other disease conditions are war-
ranted. Efficacy has been suggested for this procedure as
the first treatment for posttraumatic hypotension, particu-
larly for penetrating trauma victims requiring surgery and
for those sustaining head trauma. Elective intraoperative
use of these solutions has been associated with
hemodynamic stability and fluid sparing. However, in pa-
tients with cardiac failure, titrated dosage and careful moni-
toring are required. Increased bleeding, clinically signifi-
cant hypernatremia and allergic reactions were not asso-
ciated with hypertonic resuscitation. Hypertonic solutions
are commercially available and have been used in several
European countries. A large USA trial is been designed to
obtain approval by the FDA. Although the safety issue has
been well established, it does appear that a larger prospec-
tive, multicenter trials is required to better define the pa-
tient population to maximally benefit from hypertonic sa-
line solutions.
RESUMO
ROCHA-E-SILVA e col. Soluções hipertônicas para
reanimação de pacientes em choque. CLINICS 60(2):
159-172, 2005
O uso de soluções hipertônicas para reanimação de pa-
cientes em choque é um conceito relativamente novo. Ba-
seou-se originalmente na idéia de que uma expansão
volêmica significativa podia ser obtida às custas de um vo-
lume relativamente diminuto de infusão, aproveitando a
propriedade física de osmose. Logo ficou claro que a capa-
cidade fisiológica de produzir vasodilatação, compartilha-
da por todas as soluções hipertônicas, seria valiosa para
reperfundir territórios tornados isquêmicos pelo choque,
embora os malefícios da seqüência isquemia – reperfusão
devessem ser considerados. Pesquisa subseqüente revelou
propriedades antes insuspeitadas da reanimação hipertônica.
Verificou-se que este procedimento revertia instantanea-
mente o edema endotelial e de hemácias, com importantes
conseqüências em termos de circulação capilar. Mais recen-
temente, um conjunto de efeitos da hipertonicidade sobre
o sistema imune vem sendo estudado, mas as possíveis im-
plicações destas descobertas em relação ao cenário clínico
ainda suscitam discussão. As soluções hipertônicas estão em
uso em algumas partes do mundo, apesar de objeções le-
vantadas contra tal uso, em virtude de dados experimen-
tais derivados de experimentos de hemorragia não contro-
lada. Tais objeções não parecem se justificar em face dos
resultados obtidos numa série de ensaios clínicos e no uso
corrente destas soluções. Esta revisão procura cobrir um
pouco da história, remota e recente, deste campo do conhe-
cimento.
UNITERMOS: Tratamento de choque. Hemorragia.
Soluções hipertônicas. Circulação imune.
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